What Recombivax HB Treats: Main Uses and Benefits

RECOMBIVAX HB is applied as a prophylactic intervention to establish long-term active immunity against all known subtypes of the Hepatitis B virus (HBV). The vaccine is intended to support the prevention of acute symptomatic episodes and mitigate the risk of progression to severe, chronic liver disease. The vaccine is used across all age groups, supporting universal immunization recommendations for infants and children, and is applied to unvaccinated adults and high-risk patient populations. This specialized use contributes to appropriate protection for individuals with chronic renal disease or on hemodialysis, whose compromised immune status necessitates appropriate viral prophylaxis.

The primary therapeutic benefit contributes to mitigating the risk of serious, progressive liver damage, including advanced liver scarring (cirrhosis) and the high risk of developing liver cancer (hepatocellular carcinoma). The vaccine supports the long-term health goal related to the risk of persistent viral infection and its debilitating, chronic outcomes.

---

Quick Fact: Protection Against Chronic Risk
Main Therapeutic Benefit	Contributes to easing the overall symptom load related to chronic HBV disease.
Primary Use Context	Universal immunization and targeted prophylaxis for high-risk exposure.
Symptoms Mitigated	Helps address the risk of developing severe, acute symptoms (jaundice, fatigue) and late-stage debilitating manifestations of chronic liver failure.
Patient Groups	Infants, children, and adults, including those with chronic renal conditions.

Eligibility Map: Who can and cannot use Recombivax HB — Official Regulatory Information

The eligibility for Recombivax HB is defined by specific population criteria and patient history, as stated in regulatory labeling.

Category	Official Regulatory Statement
Populations for whom use is allowed	Individuals of all ages are eligible. The specialized Dialysis Formulation is approved for adult predialysis and dialysis patients (age ge 18).
Populations for whom use is contraindicated	Individuals with a history of severe allergic or hypersensitivity reactions (e.g., anaphylaxis) to any hepatitis B vaccine or to any component, including yeast.
Age-related eligibility rules	Approved for all age groups. Vaccination is officially delayed for low birth weight infants (under 2000 g) born to HBsAg-negative mothers until 1 month of age.
Condition-specific eligibility rules	Use in patients with moderate or severe acute febrile illness should be postponed until recovery. Immunocompromised persons may use the vaccine but are noted to have a diminished immune response.
Pregnancy and lactation eligibility status	Pregnancy is not a contraindication, but use is limited to when it is clearly needed. Use during breastfeeding is generally considered acceptable.

---

The regulatory profile establishes a core absolute contraindication based on allergic history. Beyond this, eligibility relies on specific conditional use requirements for special populations, such as needing the specialized formulation for dialysis patients or temporary deferral for acute illness. This structure defines eligibility strictly according to documented safety and response expectations for different patient groups.

Interactions with other medicines and products

The official regulatory profile for RECOMBIVAX HB focuses on pharmacodynamic interference and specific administration constraints, rather than traditional pharmacokinetic interactions involving enzymes or transporters.

Pharmacodynamic Interaction Pattern

Individuals receiving immunosuppressive therapy, which includes agents such as high-dose corticosteroids or chemotherapy, may experience a diminished immune response to the vaccine. This interaction is formally documented in regulatory labeling as a factor that may reduce the vaccine’s intended effect of seroconversion.

Administration-Timing Rules and Restrictions

The regulatory profile establishes specific, mandatory rules for co-administration with other substances:

• Do Not Mix: RECOMBIVAX HB must not be physically mixed with any other vaccine or product within the same syringe or vial. This restriction is a procedural constraint documented in the official prescribing information.
• Hepatitis B Immune Globulin (HBIG): When co-administration of the vaccine and HBIG is necessary, these products are formally required to be administered at separate injection sites (e.g., in opposite limbs) to comply with labeled restrictions.

Regulatory documentation does not specify interactions with food, alcohol, or herbal products, nor does it list specific pharmacokinetic interactions related to CYP enzymes or drug transporters.

Recombivax HB is a recombinant vaccine presenting purified Hepatitis B surface antigen (HBsAg). The HBsAg, which forms non-infectious sub-viral particles (SVPs) adsorbed onto an aluminum adjuvant, is delivered intramuscularly. The adjuvant functions as a pattern recognition receptor (PRR) ligand, activating local antigen-presenting cells (APCs), such as dendritic cells.

These APCs capture and process the HBsAg, migrating to local lymph nodes. Within the lymph node, the processed HBsAg epitopes are presented via Major Histocompatibility Complex (MHC) molecules to naïve CD4+ T lymphocytes and B lymphocytes.

This interaction initiates the clonal expansion and differentiation of antigen-specific B lymphocytes into plasma cells. These plasma cells then execute the downstream cascade of synthesizing and secreting large quantities of anti-HBs antibodies ( anti-HBs). System-level physiological consequences include the establishment of a circulating pool of these neutralizing antibodies and the formation of memory B and T cells, modulating the host's capacity for accelerated secondary response upon subsequent antigen exposure.

RECOMBIVAX HB is a sterile suspension administered by deep intramuscular (IM) injection as part of a scheduled series. The preferred injection site for adults, adolescents, and children one year and older is the deltoid muscle, while the anterolateral aspect of the thigh is designated for infants less than one year of age. Injection into the gluteal area is not recommended due to potentially diminished immune response. Subcutaneous (SC) injection is reserved only for individuals at risk of hemorrhage.

The standard administration schedule involves a series of three doses given at 0, 1, and 6 months from the initial dose time point. An alternative two-dose regimen is indicated for adolescents (ages 11–15 years), involving two doses of 10 mcg administered 4 to 6 months apart.

Dosing is determined by age and health status. The typical adult dose is 10 mcg (1.0 mL), while infants and children receive a 5 mcg (0.5 mL) dose. A distinct 40 mcg dose is indicated for adult predialysis and dialysis patients. Before use, the suspension must be shaken well to ensure homogeneity and visually inspected to confirm the absence of particulate matter.

Recombivax HB: Recent Clinical Evidence

Clinical research on Recombivax HB (Hepatitis B Vaccine, Recombinant) primarily focuses on assessing its ability to induce a protective immune response, known as seroprotection, across various age groups and patient populations. Seroprotection is generally defined as an anti-HBs antibody level of 10 mIU/mL or greater.

---

Evaluation of Immunogenicity and Efficacy

Studies have consistently reported high rates of seroprotection in healthy individuals following the recommended three-dose series. In studies involving healthy infants, children, and adolescents, seroprotection rates were frequently observed at 98% or higher. In healthy adults, rates typically ranged from 91% to 98%, depending on the age cohort, with a diminished response noted in persons over 60 years of age.

Long-term follow-up research indicates that the immune protection can persist for at least 15 years in many immunocompetent individuals who responded to the primary series, although the total duration of protection remains undefined. The need for routine booster doses in healthy persons is not currently supported by data.

---

Use in Special Populations

Clinical trials highlight that certain groups may exhibit a less robust antibody response compared to healthy adults:

• Neonates: The vaccine, when administered alongside Hepatitis B Immune Globulin (HBIG) to infants born of HBsAg-positive mothers, has demonstrated a high effectiveness rate (up to 96% in one study) in preventing chronic infection.
• Predialysis and Dialysis Patients: These adult patients generally show lower seroconversion rates. A specialized 40 mcg dose formulation is available for this population, where studies have shown that vaccination early in the course of renal disease can produce a higher response rate.

Safety Monitoring

Post-licensure monitoring and ongoing surveillance programs have supported the vaccine's established safety profile. The most commonly reported systemic adverse reactions in healthy adults during trials included fatigue, headache, and fever, while injection site reactions (such as soreness or pain) were also frequently observed.

Key Studies & References

1. Adult and Dialysis Clinical Data for RECOMBIVAX HB® [Hepatitis B Vaccine (Recombinant)]
2. RECOMBIVAX HB® (Hepatitis B Vaccine [Recombinant]) - Health Canada Product Monograph
3. What is the hepatitis B vaccination regimen in chronic kidney disease? (CME article discussing response rates in CKD/dialysis)

Official Storage and Disposal Requirements

Recombivax HB must be stored under strict refrigerated conditions to maintain its potency. Official regulatory documents specify a storage temperature range of 2 C to 8 C (36 F to 46 F).

Storage Constraints

• Do not freeze the vaccine under any circumstances. If the product is frozen, it must be discarded, as freezing destroys the antigen's effectiveness.
• The vaccine must be protected from light and stored in its original container.
• Prior to administration, the container must be shaken well and visually inspected; any product showing discoloration, extraneous particulate matter, or lack of homogeneity must be discarded.
• The vaccine must be stored out of the sight and reach of children.

Disposal

All expired or unused Recombivax HB must be discarded according to local pharmaceutical waste regulations. Vaccines obtained through the Vaccines for Children (VFC) Program have specific instructions requiring return to the State Immunization Program for destruction.